Mobile

A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PUL...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-005886-78

A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate the long-term safety of sitaxsentan and sitaxsentan plus sildenafil in subjects with PAH who are eligible for this study if B1321003 (combination therapy study) was completed or if early escape was met in B1321001 (placebo controlled study) or early discontinuation in B1321003.

Critère d'inclusion

  • pulmonary arterial hypertension

Liens